R&D JP Morgan Week 2025 – Steve Pakola On the sidelines of JP Morgan in San Francisco, editor-in-chief Jonah Comstock caught up with Steven Pakola, REGENXBIO’s chief medical officer.
News Pfizer ducks out of Sangamo haemophilia A alliance Sangamo is "surprised and disappointed" by Pfizer's decision to return rights to its gene therapy for haemophilia A after positive phase 3 results.
News Sensorion encouraged by deafness gene therapy data Sensorion's gene therapy for otoferlin-related hearing loss has shown early signs of improving hearing in two toddlers in a phase 1/2 trial.
News uniQure rockets on map to market for Huntington's therapy uniQure says it has reached agreement with the FDA on a pathway to accelerated approval for its much-anticipated Huntington's disease gene therapy.
News FDA probing cancer cases with Bluebird's CALD gene therapy The FDA is scrutinising reports of haematological cancers in patients treated with bluebird bio's Skysona gene therapy for neurological disease CALD
R&D Partner Content 8th Gene Therapy Development Summit With 14 new gene therapy approvals in the last 18 months, billion-dollar collaborations, and the development of treatments for more common conditions, the gene therapy field is rapidly gaining mome
News MSD stops trials of BTK inhibitor for blood cancers MSD has stopped development of BTK inhibitor nemtabrutinib, acquired via its $2.7bn takeover of ArQule, after trial results pointed to a safety issue.
Sales & Marketing Sponsored Securing your ROI: Turning post-acquisition integration into... Join Forinnovia and Little Cube Consulting for a webinar on securing post-acquisition ROI.